Merck's potential blockbuster cholesterol pill succeeds in late-stage studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.
The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade.
Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes.
Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol.
BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies.
The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said.
However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial.
Merck has not given the details on LDL-C reduction for enlicitide.
The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin.
Shares of Merck were up 2% in premarket trading.
Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Starbucks accelerates new staffing model to all North American stores
By Waylon Cunningham (Reuters) -Starbucks CEO Brian Niccol told Reuters on Tuesday that he would accelerate the rollout of the coffeehouse chain's new staffing and service model, aiming for all 18,000 North American stores by summer's end, rather than the initial plan for just a third of U.S. stores by year-end. Niccol says the model is a foundational element of his turnaround strategy for the company, as he bets on an improved in-store customer experience to reclaim the sales growth that has eluded Starbucks in recent quarters. Niccol said early tests of the model have sped up service times and grown sales, without providing specifics. 'We've learned, and now we know what we need to do, so let's scale it,' he told Reuters at the company's three-day leadership summit in Las Vegas on Tuesday. The Green Apron model includes in-store technology to more efficiently sequence orders, as well as a dedicated barista for drive-through orders. Starbucks rolled out the service changes to 700 stores initially. During the company's April 29 quarterly earnings call, Niccol said it would be introduced in a third of U.S. stores by year-end. Niccol took over as Starbucks CEO in September with a plan to return the chain to its coffeehouse roots, focusing on the in-store experience and away from a reliance on mobile and to-go orders, in what the company calls "Back to Starbucks.' The goal is to get baristas to get customers their orders in four minutes or less. He did not share any financial figures about the cost of the Green Apron model's deployment, but said the company would host an investor day in 2026. The Las Vegas summit, the company's first since 2019, is hosting more than 14,000 managers and other company leaders. Analysts and investors have wondered how long Niccol will need to turn the company around. Shares have gained 11% over the last five years, compared with an 88% rise in the broad-market S&P 500. TD Cowen recently downgraded its rating of Starbucks to "hold" from "buy", saying in part that it believed Niccol's turnaround would take longer than expected to deliver results. Niccol said the transition will take time. Starbucks has not issued annual guidance, and Niccol told investors in an earnings call earlier this year that earnings-per-share 'shouldn't be used as a measure of our success' at this stage, instead pointing to in-store metrics like average wait times for orders. He said the transition's effect on earnings would be temporary. On Tuesday, he emphasized his goal isn't to achieve short-term performance solely through cost reduction. As Starbucks increases investments in its labor and elsewhere, Niccol said he would be "ruthless" in cutting expenses not related to the company's turnaround. 'We have to be critical of where we're spending if it's not driving toward the Back to Starbucks strategy and growth programs.'
WebMD
an hour ago
- WebMD
FDA OKs New Shot to Protect Babies Against RSV
June 10, 2025 – The FDA has approved a new shot to prevent respiratory syncytial virus (RSV) infection in babies during their first RSV season, which typically lasts from fall through spring. Clesrovimab, which is sold as Enflonsia, is the first and only RSV protection for babies that uses the same dose for all infants, regardless of their body weight. This makes it a simpler and more precise option that ensures reliable protection throughout the RSV season. RSV is a common virus that spreads during colder months through coughs, sneezes, direct contact, or contaminated surfaces. It typically causes mild, cold-like symptoms. Infants (especially those under 6 months) and older adults are more likely to have a severe RSV infection. RSV can cause bronchiolitis (inflammation of small airways) and pneumonia, sometimes leading to hospitalization. Because it's the leading cause of hospitalization in infants, vaccines and preventive treatments are the best way to protect them. Merck, the maker of the new preventive, said the FDA's decision was based on two clinical trials. In the first trial, a single dose of Enflonsia was given to newborns, both preterm and full-term, and reduced RSV severe lung infections by 60% and hospitalizations by 84% over five months, compared to a placebo. The second trial showed Enflonsia was as effective and safe as an older RSV medicine (palivizumab) for babies at higher risk, such as those born very early or with lung or heart issues. The clinical trials also showed that Enflonsia was just as safe on its own or with other routine childhood vaccines. "Enflonsia combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV," Octavio Ramilo, MD, chair of the Department of Infectious Diseases at St. Jude Children's Research Hospital and investigator for the clinical trials, said in a statement. The Enflonsia shot contains ready-made antibodies that help newborns and infants fight off RSV before it can cause serious lung infections. It uses a single, non-weight-based, 105-mg dose that gives fast and lasting protection for about five months. Babies born during RSV season should get the shot at birth, while those born before the season should get it just before it starts. The preventive is given as an injection in the baby's thigh.
Yahoo
an hour ago
- Yahoo
JERA close to signing deal for 1 MTPA of LNG from Commonwealth, sources say
By Curtis Williams HOUSTON (Reuters) -U.S. liquefied natural gas developer Commonwealth LNG is close to signing a deal with Japan's biggest power generator, JERA, to supply it with 1 million metric tons per annum (mtpa) of LNG from its proposed export facility in Louisiana, two sources told Reuters. The deal would run for 20 years and bring Commonwealth LNG to 8 mtpa committed under long-term contracts. The company has said publicly that it wants to get contracts for at least 8 mtpa of its 9.5 mtpa LNG export terminal capacity to give the project the financial go ahead. The U.S. is the largest exporter of LNG in the world and based on projects under construction and those expected to get the financial go ahead this year, the country could triple its export capacity by 2030. "They have agreed to terms on the deal and should be signing it soon," one of the sources familiar with the negotiations told Reuters. Commonwealth LNG did not respond to a request for comment. JERA declined to comment. Commonwealth was one of the projects impacted by a pause on new LNG export licenses imposed by former President Joe Biden pending a study on the economic and environmental impact of further U.S. LNG expansion. That freeze was lifted by the Trump administration, which has promised to unleash American energy. In February Commonwealth received a conditional non-free trade agreement (non-FTA) export authorization from the Department of Energy. Commonwealth said it expects to reach a final investment decision in September 2025 for the project, with first LNG production expected in the first quarter of 2029. In May JERA announced that it had signed an agreement with NextDecade to purchase 2 mtpa of LNG from its Rio Grande project's fifth liquefaction facility.
